Content overview: “Compass Pathways CEO Kabir Nath: Psychedelic Therapy Will ‘Go Slow Before We Go Fast’ Ahea”. Compass Pathways CEO Kabir Nath says the mental health company is taking a measured approach as its psilocybin-based therapy for treatment-resistant depression heads toward regulatory review this year. In a recent interview, Nath emphasized that Compass will “go slow before we go fast,” signaling a deliberate strategy focused on safety, data quality, and building trust with regulators and clinicians. The London-based company is developing COMP360, a synthetic formulation of psilocybin administered alongside psychological support, and is currently advancing late-stage clinical trials.
With a potential FDA submission on the horizon, Compass is positioning itself as a leader in the emerging psychedelic medicine space, but Nath’s comments suggest a cautious path to commercialization. Investors and patients alike are watching closely, as the company’s approach could set the tone for the entire industry. For the complete material, the listing points back to the source inside the network.